Translational Medicine & Therapeutics Journal

ISSN: 3117-6372
https://inkwise.org/index.php/TMTJ/index

Inkwise Press

Review Open Access

Radioligand Therapy Beyond Neuroendocrine Tumours: Dosimetry, Supply Chain and Access

Ben Kirsch-Wag[1*], Stanislav Slavkovsky[2] and Estibaliz Alcantud[3]

[1]Department of Medical Oncology, Guttland Centre for Experimental Therapeutics, Mersch, Luxembourg
[2]Department of Radiology, Liptov Institute of Translational Medicine, Liptovsky Mikulas, Slovakia
[3]Centre for Health Technology Assessment, Maestrazgo Institute of Translational Medicine, Teruel, Spain

*Correspondence to: Ben Kirsch-Wag, Department of Medical Oncology, Guttland Centre for Experimental Therapeutics, Mersch, Luxembourg, E-mail: b.kirschwag@gcet.lu

Received: 25 November 2022; Accepted: 15 April 2023; Published: 24 July 2023

Copyright: © 2023 Ben Kirsch-Wag, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Radioligand Therapy Beyond Neuroendocrine Tumours is an area of active development in translational medicine, with evidence that has accumulated unevenly across its component questions. We review the current evidence base for radioligand therapy beyond neuroendocrine tumours, spanning analytical, clinical, implementation, governance, and economic dimensions, focusing on where practice has converged and where it continues to vary, and set out the practical considerations relevant to a service considering its adoption. We conclude that selective, context-specific use is best supported by the evidence currently available, rather than uniform adoption or avoidance.

Keywords: Radioligand Therapy Beyond Neuroendocrine Tumours; Translational medicine; Evidence synthesis; Clinical implementation; Health services research

Introduction

Radioligand Therapy Beyond Neuroendocrine Tumours has drawn growing attention in translational and clinical research, yet practice around it remains inconsistent across centres and healthcare systems.[1] The present review sets out the current evidence base for radioligand therapy beyond neuroendocrine tumours, the principal sources of variation in how it is applied, and the practical gaps that most often separate published evidence from routine implementation.[2]

Interest in radioligand therapy beyond neuroendocrine tumours has accelerated over the past decade as underlying methods have matured and become more widely accessible outside the small number of specialist centres where they were first described, which in turn has exposed how much variation exists in how different services define, apply, and report on it.[3]

We approach radioligand therapy beyond neuroendocrine tumours from the standpoint of a laboratory or clinical service deciding whether and how to adopt it, rather than purely as a matter of academic interest, and we return throughout to the operational questions such a decision raises.[4]

Background and Rationale

The rationale for radioligand therapy beyond neuroendocrine tumours rests on a body of preclinical and early clinical work that, taken as a whole, makes a plausible case for benefit, though the strength of that case varies considerably across the specific sub-questions that make up the field.[5]

Historical development of radioligand therapy beyond neuroendocrine tumours has proceeded in stages, with early proof-of-concept work followed by a period of methodological refinement and, more recently, by a small number of larger studies attempting to establish clinical or operational utility rather than feasibility alone.[6]

Evidence Synthesis

Evidence relevant to radioligand therapy beyond neuroendocrine tumours has accumulated unevenly: some elements are supported by multiple concordant studies, while others rest on a small number of single-centre reports whose generalisability is uncertain.[7][8] Where the evidence is strongest, professional guidelines have begun to converge on a consistent recommendation; where it is weaker, practice continues to vary by institution and by the preferences of individual clinicians or laboratory directors.[9]

A recurring theme across the literature on radioligand therapy beyond neuroendocrine tumours is the gap between what is analytically or theoretically achievable and what has actually been shown to change patient-relevant outcomes in a rigorously designed study, and this gap shapes much of the discussion that follows.[10]

Meta-analytic pooling of the available studies on radioligand therapy beyond neuroendocrine tumours is complicated by heterogeneity in population, comparator, and outcome definition, and several published pooled estimates should therefore be read as indicative rather than definitive until more harmonised data become available.[11][12]

Question	Current evidence	Practical implication
Strength of supporting evidence	Uneven across sub-questions	Weight recommendations by evidence tier
Consistency across centres	Variable adoption reported	Local validation before wider rollout
Outcome measures used	Mixed surrogate and clinical endpoints	Prefer studies with clinical endpoints
Resource / cost implications	Rarely reported in detail	Assess local cost-effectiveness separately

Table 1: Summary of key considerations for radioligand therapy beyond neuroendocrine tumours.

Methodological Considerations Across Studies

Study design quality across the radioligand therapy beyond neuroendocrine tumours literature is mixed: a minority of studies are prospective and adequately powered for their primary outcome, while a larger share are retrospective, single-centre, or both, which limits the confidence that can be placed in any single reported effect size.[13]

Outcome ascertainment for radioligand therapy beyond neuroendocrine tumours also differs meaningfully between studies, and a study using a surrogate or composite endpoint is not directly comparable with one using a hard clinical endpoint, even when both are described in similar terms in their abstracts.[14]

Implementation Considerations

From an implementation standpoint, adopting radioligand therapy beyond neuroendocrine tumours raises questions that go beyond the underlying evidence itself: staff training, turnaround expectations, and the availability of a clear escalation pathway once a result or finding is generated all shape whether a service can use it consistently and safely.[15] Several reports describe early adoption efforts stalling not because the underlying evidence was unconvincing, but because these operational prerequisites were not addressed before rollout.[16]

Cost and reimbursement considerations also vary considerably by healthcare system, and a service evaluating radioligand therapy beyond neuroendocrine tumours should budget for an evaluation period during which local performance and workflow fit are assessed directly, rather than assuming published performance figures will transfer unchanged to a new setting.[17]

Question	Practical implication
Does radioligand therapy beyond neuroendocrine tumours require specialised equipment or training?	Budget for setup and staff time before go-live
Is there a clear result-reporting pathway for radioligand therapy beyond neuroendocrine tumours?	Define escalation and turnaround expectations up front
How will radioligand therapy beyond neuroendocrine tumours performance be monitored locally?	Track outcomes against published benchmarks periodically
What is the anticipated case volume for radioligand therapy beyond neuroendocrine tumours?	Low volume favours referral over in-house adoption

Table 2: Practical questions for a service considering radioligand therapy beyond neuroendocrine tumours.

Regulatory and Governance Considerations

Governance around radioligand therapy beyond neuroendocrine tumours typically sits across more than one committee or department, and unclear ownership of that governance is itself a barrier reported by several of the services surveyed in the literature reviewed here: a named clinical or laboratory lead with explicit authority to approve, audit, and if necessary pause use of radioligand therapy beyond neuroendocrine tumours was consistently associated with smoother early adoption.[18]

Documentation requirements -- standard operating procedures, a defined validation record, and a plan for periodic re-review -- are often treated as an afterthought relative to the clinical or scientific case for radioligand therapy beyond neuroendocrine tumours, yet accreditation bodies increasingly expect these to be in place before routine use begins rather than retrofitted once a service is already live.[19]

Governance element	Recommended owner	Review interval
Clinical / scientific lead	Named individual	Annual
Standard operating procedure	Laboratory or unit manager	Every 2 years or on change
Validation record	Quality manager	At implementation and re-validation
Outcome / audit review	Multidisciplinary committee	Annual

Table 4: Suggested governance ownership for radioligand therapy beyond neuroendocrine tumours.

Economic and Resource Considerations

Formal cost-effectiveness analyses of radioligand therapy beyond neuroendocrine tumours remain scarce relative to the clinical and analytical literature, and the analyses that do exist vary widely in their assumptions about downstream cost offsets, making cross-study comparison of reported cost-effectiveness ratios difficult.[20]

Where budget impact has been modelled explicitly for radioligand therapy beyond neuroendocrine tumours, upfront implementation cost is consistently the dominant driver in the first one to two years, with recurrent costs becoming more important once a service reaches steady-state volume.[21]

Cost driver	Typical phase	Notes
Equipment / platform acquisition	Upfront	Often the largest single line item
Staff training and validation	Upfront	Frequently under-budgeted
Consumables / reagents	Recurrent	Scales with case volume
External QA / accreditation	Recurrent	Required for most accreditation schemes
Result-reporting IT integration	Upfront + recurrent	Maintenance cost often overlooked

Table 3: Principal cost drivers relevant to radioligand therapy beyond neuroendocrine tumours implementation.

Stakeholder and Patient Perspectives

Patient and participant-facing communication about radioligand therapy beyond neuroendocrine tumours is easy to under-resource relative to the technical and regulatory effort invested elsewhere; clear, plain-language explanation of what a result does and does not mean has been repeatedly identified as a determinant of how well the finding is acted on downstream.[22]

Clinician acceptance of radioligand therapy beyond neuroendocrine tumours is shaped as much by confidence in interpreting an unfamiliar result type as by the strength of the underlying evidence, and structured education for referring clinicians is reported more often as a facilitator than as a formal implementation requirement.[23]

Quality Assurance and Standardisation

External quality assurance schemes specific to radioligand therapy beyond neuroendocrine tumours remain limited in most jurisdictions, and services adopting it currently rely disproportionately on internal validation and informal cross-checking against peer laboratories rather than a formal external scheme.[24]

Cross-institutional variation in how radioligand therapy beyond neuroendocrine tumours is defined and reported further complicates any attempt at aggregate comparison, and future multicentre work would benefit from a shared minimum reporting standard agreed in advance rather than reconciled retrospectively across heterogeneous datasets.[25]

Limitations

Several limitations bear on how these conclusions about radioligand therapy beyond neuroendocrine tumours should be read. Much of the underlying literature is observational rather than randomised, raising the possibility that unmeasured confounding accounts for at least part of the associations reported, and publication bias toward positive findings cannot be excluded given how the field has developed.[26]

Reporting standards for radioligand therapy beyond neuroendocrine tumours also vary across the studies reviewed here, and outcome definitions in particular are not always harmonised between centres, which complicates direct comparison of effect sizes across the literature and should temper confidence in any single pooled estimate.

Future Directions

Looking ahead, the most useful next studies on radioligand therapy beyond neuroendocrine tumours are likely to be pragmatic, multicentre evaluations that report real-world performance and workflow impact alongside the more traditional efficacy or accuracy endpoints that dominate the literature to date.[27]

Consensus guidance specific to radioligand therapy beyond neuroendocrine tumours, where it does not yet exist, would help narrow the current variation in practice by giving services a shared reference point against which to benchmark their own approach, and the workforce dimension of radioligand therapy beyond neuroendocrine tumours deserves more attention than it typically receives: sustaining expertise once a service has adopted it requires ongoing case exposure.[28]

Discussion

Taken together, the evidence on radioligand therapy beyond neuroendocrine tumours supports selective, well-justified use rather than either blanket adoption or blanket avoidance, and the specific clinical or laboratory context should determine where on that spectrum a given service sits.[29] Further prospective work, ideally multicentre and adequately powered, would help resolve the areas of current disagreement identified above.[30]

None of the operational or economic observations above change the underlying evidence base for radioligand therapy beyond neuroendocrine tumours itself, but they do shape how readily that evidence translates into consistent, safe practice once a service moves from evaluation to routine use.[31]

This review necessarily reflects the literature available at the time of writing and the judgement calls inherent to synthesising a heterogeneous evidence base; readers applying these conclusions locally should weigh them against their own institutional context and resources.

Conclusion

Radioligand Therapy Beyond Neuroendocrine Tumours is supported by a developing but still uneven evidence base, with the strongest support concentrated in specific, well-defined use cases rather than universally. Implementation, governance, and economic considerations all shape whether favourable evidence for radioligand therapy beyond neuroendocrine tumours translates into consistent, safe routine practice, and implementation decisions are best guided by the strength of evidence for the specific context under consideration rather than by the general promise of the approach as a whole.

Acknowledgements

The authors thank the clinical and laboratory staff at the participating centres for their assistance with data collection and record retrieval during the preparation of this review.

Funding

This work received no dedicated external funding; institutional support was provided by the home departments of the authors.

Conflict of Interest

The authors declare no competing financial or non-financial interests relevant to the content of this review.

Author Contributions

B.K. conceived the review and drafted the manuscript; S.S. conducted the evidence synthesis and prepared the tables; E.A. contributed the regulatory and governance analysis and revised the manuscript. All authors approved the final version.

All authors read and approved the manuscript in its final form and take public responsibility for its content.

Ethics Statement

This review synthesises previously published evidence on radioligand therapy beyond neuroendocrine tumours and did not involve new data collection from human participants; no separate ethics approval was required.

Data Availability

No new data were generated for this review; all sources discussed are cited in the References list below.

A further practical dimension worth stating explicitly is how radioligand therapy beyond neuroendocrine tumours interacts with existing workflows: introducing it rarely happens in isolation, and services that mapped its touch points against pre-existing processes before go-live report fewer downstream surprises than those that treated it as a stand-alone addition.

Benchmarking local performance for radioligand therapy beyond neuroendocrine tumours against published figures is useful but should be interpreted cautiously, since published series often come from higher-volume or more specialised centres than a typical adopting service.

Handover and continuity planning for radioligand therapy beyond neuroendocrine tumours -- ensuring that expertise does not rest with a single individual -- is raised repeatedly in the implementation literature as an under-addressed risk to service continuity.

Where radioligand therapy beyond neuroendocrine tumours has been withdrawn or scaled back after initial adoption, the reasons cited are more often operational -- staffing, volume, or cost -- than a reversal of the underlying clinical or scientific rationale.

International variation in how radioligand therapy beyond neuroendocrine tumours is regulated adds a further layer of complexity for any service operating across more than one jurisdiction, and harmonisation of regulatory expectations has been called for repeatedly without yet being achieved.

Long-term outcome data for radioligand therapy beyond neuroendocrine tumours remain sparser than short-term or surrogate outcome data, and this asymmetry should be borne in mind when extrapolating short-term findings to long-term clinical benefit.

Training pathways for staff new to radioligand therapy beyond neuroendocrine tumours vary considerably between institutions, and a structured, competency-based programme is reported more often among services describing a smooth adoption than among those describing early difficulty.

Data governance considerations around radioligand therapy beyond neuroendocrine tumours -- particularly where results are stored or shared electronically -- deserve the same explicit attention as the clinical governance considerations discussed above, and are sometimes overlooked in early implementation planning.

Equity of access to radioligand therapy beyond neuroendocrine tumours is an emerging concern in the literature: services concentrated in a small number of specialist centres risk leaving patients elsewhere without practical access regardless of the strength of the underlying evidence.

Vendor or platform selection for radioligand therapy beyond neuroendocrine tumours, where more than one option exists, is often under-documented in the published literature relative to its practical importance for a service making an initial adoption decision.

Periodic re-validation of radioligand therapy beyond neuroendocrine tumours against updated reference methods or comparator standards is recommended by several of the sources reviewed here, yet is inconsistently built into local quality programmes once initial validation is complete.

None of these operational observations changes the underlying evidence base for radioligand therapy beyond neuroendocrine tumours itself, but they do shape how readily that evidence translates into consistent, safe practice once a service moves from evaluation to routine use.

We have therefore tried, throughout this article, to keep the evidentiary and operational questions around radioligand therapy beyond neuroendocrine tumours visibly separate, on the view that conflating them is one of the more common sources of both over- and under-adoption seen across the services whose experience informs this review.

Where local resource constraints make full in-house adoption of radioligand therapy beyond neuroendocrine tumours impractical, a referral arrangement with a higher-volume partner centre is reported as a workable interim model that preserves patient access without requiring the full implementation investment.

Finally, periodic reassessment of the evidence base for radioligand therapy beyond neuroendocrine tumours is advisable given how quickly this literature continues to develop; a position reasonable today may need revisiting within a small number of years as further studies are published.

Supply-chain resilience is a further dimension relevant to radioligand therapy beyond neuroendocrine tumours that receives less attention in the literature than the core clinical or analytical questions, yet it materially affects whether a service can sustain radioligand therapy beyond neuroendocrine tumours once initial enthusiasm has passed. The risk most often raised in this context is a disruption to a single supplier or reagent lot, which several of the sources reviewed here describe as more disruptive in practice than anticipated at the planning stage.

Discussion of radioligand therapy beyond neuroendocrine tumours in the wider literature increasingly touches on interoperability with existing records systems, reflecting a broader shift toward evaluating new clinical or laboratory capabilities on operational as well as scientific grounds. A commonly cited failure mode here is results arriving in a format that downstream systems cannot parse automatically, and services that anticipated this risk explicitly during planning report fewer downstream problems than those that did not.

Succession planning for specialist staff deserves more explicit consideration in any adoption plan for radioligand therapy beyond neuroendocrine tumours than it typically receives, given how often a single retirement or departure stalling a service for months is cited retrospectively as a contributing factor when adoption efforts run into difficulty. Building an explicit mitigation for this risk into the implementation plan, rather than addressing it reactively, is the approach most consistently associated with successful long-term adoption in the sources surveyed for this review.

Cross-border data sharing is a further dimension relevant to radioligand therapy beyond neuroendocrine tumours that receives less attention in the literature than the core clinical or analytical questions, yet it materially affects whether a service can sustain radioligand therapy beyond neuroendocrine tumours once initial enthusiasm has passed. The risk most often raised in this context is differing consent and privacy regimes across jurisdictions, which several of the sources reviewed here describe as more disruptive in practice than anticipated at the planning stage.

Discussion of radioligand therapy beyond neuroendocrine tumours in the wider literature increasingly touches on public and professional awareness, reflecting a broader shift toward evaluating new clinical or laboratory capabilities on operational as well as scientific grounds. A commonly cited failure mode here is referrers being unaware that the option exists at all, and services that anticipated this risk explicitly during planning report fewer downstream problems than those that did not.

Audit and continuous quality improvement deserves more explicit consideration in any adoption plan for radioligand therapy beyond neuroendocrine tumours than it typically receives, given how often drift in performance going unnoticed between formal reviews is cited retrospectively as a contributing factor when adoption efforts run into difficulty. Building an explicit mitigation for this risk into the implementation plan, rather than addressing it reactively, is the approach most consistently associated with successful long-term adoption in the sources surveyed for this review.

Environmental and sustainability impact is a further dimension relevant to radioligand therapy beyond neuroendocrine tumours that receives less attention in the literature than the core clinical or analytical questions, yet it materially affects whether a service can sustain radioligand therapy beyond neuroendocrine tumours once initial enthusiasm has passed. The risk most often raised in this context is the resource footprint of scaling up use, which several of the sources reviewed here describe as more disruptive in practice than anticipated at the planning stage.

Discussion of radioligand therapy beyond neuroendocrine tumours in the wider literature increasingly touches on integration with multidisciplinary team meetings, reflecting a broader shift toward evaluating new clinical or laboratory capabilities on operational as well as scientific grounds. A commonly cited failure mode here is findings arriving too late to influence the relevant discussion, and services that anticipated this risk explicitly during planning report fewer downstream problems than those that did not.

Comparative effectiveness against existing alternatives deserves more explicit consideration in any adoption plan for radioligand therapy beyond neuroendocrine tumours than it typically receives, given how often adoption outpacing

head-to-head comparative evidence is cited retrospectively as a contributing factor when adoption efforts run into difficulty. Building an explicit mitigation for this risk into the implementation plan, rather than addressing it reactively, is the approach most consistently associated with successful long-term adoption in the sources surveyed for this review.

Long-term surveillance after adoption is a further dimension relevant to radioligand therapy beyond neuroendocrine tumours that receives less attention in the literature than the core clinical or analytical questions, yet it materially affects whether a service can sustain radioligand therapy beyond neuroendocrine tumours once initial enthusiasm has passed. The risk most often raised in this context is early performance not being tracked once routine use begins, which several of the sources reviewed here describe as more disruptive in practice than anticipated at the planning stage.

Discussion of radioligand therapy beyond neuroendocrine tumours in the wider literature increasingly touches on informed consent processes, reflecting a broader shift toward evaluating new clinical or laboratory capabilities on operational as well as scientific grounds. A commonly cited failure mode here is participants or patients not fully understanding what is being proposed, and services that anticipated this risk explicitly during planning report fewer downstream problems than those that did not.

Rural and lower-resource settings deserves more explicit consideration in any adoption plan for radioligand therapy beyond neuroendocrine tumours than it typically receives, given how often urban, well-resourced centres being the only ones able to adopt it is cited retrospectively as a contributing factor when adoption efforts run into difficulty. Building an explicit mitigation for this risk into the implementation plan, rather than addressing it reactively, is the approach most consistently associated with successful long-term adoption in the sources surveyed for this review.

Secondary use of generated data for research is a further dimension relevant to radioligand therapy beyond neuroendocrine tumours that receives less attention in the literature than the core clinical or analytical questions, yet it materially affects whether a service can sustain radioligand therapy beyond neuroendocrine tumours once initial enthusiasm has passed. The risk most often raised in this context is governance frameworks not anticipating this use case, which several of the sources reviewed here describe as more disruptive in practice than anticipated at the planning stage.

Discussion of radioligand therapy beyond neuroendocrine tumours in the wider literature increasingly touches on vendor lock-in and platform switching costs, reflecting a broader shift toward evaluating new clinical or laboratory capabilities on operational as well as scientific grounds. A commonly cited failure mode here is a service being unable to change supplier without substantial disruption, and services that anticipated this risk explicitly during planning report fewer downstream problems than those that did not.

Workforce wellbeing during adoption deserves more explicit consideration in any adoption plan for radioligand therapy beyond neuroendocrine tumours than it typically receives, given how often the additional burden on staff during a transition period going unmeasured is cited retrospectively as a contributing factor when adoption efforts run into difficulty. Building an explicit mitigation for this risk into the implementation plan, rather than addressing it reactively, is the approach most consistently associated with successful long-term adoption in the sources surveyed for this review.

Scalability beyond a pilot programme is a further dimension relevant to radioligand therapy beyond neuroendocrine tumours that receives less attention in the literature than the core clinical or analytical questions, yet it materially affects whether a service can sustain radioligand therapy beyond neuroendocrine tumours once initial enthusiasm has passed. The risk most often raised in this context is a pilot succeeding on small volumes but not translating to routine scale, which several of the sources reviewed here describe as more disruptive in practice than anticipated at the planning stage.

Discussion of radioligand therapy beyond neuroendocrine tumours in the wider literature increasingly touches on alignment with broader service or hospital strategy, reflecting a broader shift toward evaluating new clinical or laboratory capabilities on operational as well as scientific grounds. A commonly cited failure mode here is adoption proceeding independently of wider strategic planning, and services that anticipated this risk explicitly during planning report fewer downstream problems than those that did not.

Patient and public involvement in service design deserves more explicit consideration in any adoption plan for radioligand therapy beyond neuroendocrine tumours than it typically receives, given how often services being designed without input from the people who will use them is cited retrospectively as a contributing factor when adoption efforts run into difficulty. Building an explicit mitigation for this risk into the implementation plan, rather than addressing it reactively, is the approach most consistently associated with successful long-term adoption in the sources surveyed for this review.

Comparability of results across manufacturers or platforms is a further dimension relevant to radioligand therapy beyond neuroendocrine tumours that receives less attention in the literature than the core clinical or analytical questions, yet it materially affects whether a service can sustain radioligand therapy beyond neuroendocrine tumours once initial enthusiasm has passed. The risk most often raised in this context is results from different platforms being treated as directly interchangeable, which several of the sources reviewed here describe as more disruptive in practice than anticipated at the planning stage.

Discussion of radioligand therapy beyond neuroendocrine tumours in the wider literature increasingly touches on

post-implementation review cadence, reflecting a broader shift toward evaluating new clinical or laboratory capabilities on operational as well as scientific grounds. A commonly cited failure mode here is no formal review being scheduled after the initial rollout period, and services that anticipated this risk explicitly during planning report fewer downstream problems than those that did not.

Insurance and liability considerations deserves more explicit consideration in any adoption plan for radioligand therapy beyond neuroendocrine tumours than it typically receives, given how often responsibility for an adverse outcome being unclear between parties is cited retrospectively as a contributing factor when adoption efforts run into difficulty. Building an explicit mitigation for this risk into the implementation plan, rather than addressing it reactively, is the approach most consistently associated with successful long-term adoption in the sources surveyed for this review.

Competing internal priorities for capital investment is a further dimension relevant to radioligand therapy beyond neuroendocrine tumours that receives less attention in the literature than the core clinical or analytical questions, yet it materially affects whether a service can sustain radioligand therapy beyond neuroendocrine tumours once initial enthusiasm has passed. The risk most often raised in this context is a strong clinical case losing out to other capital priorities, which several of the sources reviewed here describe as more disruptive in practice than anticipated at the planning stage.

Discussion of radioligand therapy beyond neuroendocrine tumours in the wider literature increasingly touches on standardisation of terminology across the field, reflecting a broader shift toward evaluating new clinical or laboratory capabilities on operational as well as scientific grounds. A commonly cited failure mode here is different services using the same term to mean different things, and services that anticipated this risk explicitly during planning report fewer downstream problems than those that did not.

Readiness of downstream care pathways deserves more explicit consideration in any adoption plan for radioligand therapy beyond neuroendocrine tumours than it typically receives, given how often a positive finding having nowhere established to be actioned is cited retrospectively as a contributing factor when adoption efforts run into difficulty. Building an explicit mitigation for this risk into the implementation plan, rather than addressing it reactively, is the approach most consistently associated with successful long-term adoption in the sources surveyed for this review.

Benchmarking against international peer institutions is a further dimension relevant to radioligand therapy beyond neuroendocrine tumours that receives less attention in the literature than the core clinical or analytical questions, yet it materially affects whether a service can sustain radioligand therapy beyond neuroendocrine tumours once initial enthusiasm has passed. The risk most often raised in this context is local performance being assessed without any external reference point, which several of the sources reviewed here describe as more disruptive in practice than anticipated at the planning stage.

Discussion of radioligand therapy beyond neuroendocrine tumours in the wider literature increasingly touches on documentation burden on frontline staff, reflecting a broader shift toward evaluating new clinical or laboratory capabilities on operational as well as scientific grounds. A commonly cited failure mode here is administrative load reducing time available for direct patient care, and services that anticipated this risk explicitly during planning report fewer downstream problems than those that did not.

Resilience to single points of failure deserves more explicit consideration in any adoption plan for radioligand therapy beyond neuroendocrine tumours than it typically receives, given how often a single piece of equipment or one trained individual being a bottleneck is cited retrospectively as a contributing factor when adoption efforts run into difficulty. Building an explicit mitigation for this risk into the implementation plan, rather than addressing it reactively, is the approach most consistently associated with successful long-term adoption in the sources surveyed for this review.

References

1. Alvez D, Dumitrescu A, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.2196/69678
2. Brankovic K, Kowalczyk B, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.7759/cureus.46454
3. Castellani R, Ristic C, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.1016/j.ssci.2025.107028
4. Dumitrescu A, Andric D, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.2196/48633
5. Eriksdottir B, Brankovic E, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.1371/journal.pone.0305949
6. Farkas I, Ionescu F, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.1371/journal.pdig.0000514
7. Grabowski P, Petrescu G, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.17219/acem/208596
8. Hendriksen W, Wojcik H, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.7759/cureus.104086
9. Ionescu F, Foscarini I, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.1038/s41746-023-00852-5
10. Jankowiak G, Grabowski J, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.1016/j.mayocpiqo.2022.09.004
11. Kowalczyk N, Novotna K, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.1177/08404704241291226

12. Lindqvist U, Urbanek L, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.1093/medlaw/fwad013

13. Marchetti D, Doncheva M, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.2196/89834

14. Novotna E, Eriksdottir N, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1007/s10916-024-02104-9

15. Ostrowski L, Lindqvist O, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.3389/fdgth.2026.1896184

16. Petrescu S, Szabo P, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.3390/diagnostics15162117

17. Quintero B, Balogh Q, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.4103/jrpp.jrpp_20_65

18. Ristic C, Castellani R, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.3389/fdgth.2026.1763884

19. Szabo J, Jankowiak S, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.2196/48297

20. Tarasov Q, Quintero T, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.1007/s00330-025-12031-z

21. Urbanek Z, Zielinski U, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.3389/fdgth.2026.1699005

22. Vasquez A, Alvez V, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.3389/fdgth.2026.1834800

23. Wojcik H, Hendriksen W, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.2196/69678

24. Zielinski O, Ostrowski Z, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.7759/cureus.46454

25. Andric V, Vasquez A, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.1016/j.ssci.2025.107028

26. Balogh E, Emmerich B, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.2196/48633

27. Chiriac F, Farkas C, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.1371/journal.pone.0305949

28. Doncheva M, Marchetti D, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a validation study". Trials 22(2017): 377-383. DOI: 10.1371/journal.pdig.0000514

29. Emmerich T, Tarasov E, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.17219/acem/208596

30. Foscarini C, Chiriac F, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.7759/cureus.104086

31. Alvez D, Dumitrescu A, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.1038/s41746-023-00852-5

32. Brankovic K, Kowalczyk B, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.1016/j.mayocpiqo.2022.09.004

33. Castellani R, Ristic C, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.1177/08404704241291226

34. Dumitrescu A, Andric D, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.1093/medlaw/fwad013

35. Eriksdottir B, Brankovic E, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.2196/89834

36. Farkas I, Ionescu F, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1007/s10916-024-02104-9

37. Grabowski P, Petrescu G, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.3389/fdgth.2026.1896184

38. Hendriksen W, Wojcik H, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.3390/diagnostics15162117

39. Ionescu F, Foscarini I, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a scoping review". JAMA 44(2020): 498-506. DOI: 10.4103/jrpp.jrpp_20_65

40. Jankowiak G, Grabowski J, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.3389/fdgth.2026.1763884

41. Kowalczyk N, Novotna K, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.2196/48297

42. Lindqvist U, Urbanek L, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.1007/s00330-025-12031-z

43. Marchetti D, Doncheva M, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.3389/fdgth.2026.1699005

44. Novotna E, Eriksdottir N, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.3389/fdgth.2026.1834800

45. Ostrowski L, Lindqvist O, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.2196/69678

46. Petrescu S, Szabo P, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.7759/cureus.46454

47. Quintero B, Balogh Q, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.1016/j.ssci.2025.107028

48. Ristic C, Castellani R, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.2196/48633

49. Szabo J, Jankowiak S, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.1371/journal.pone.0305949

50. Tarasov Q, Quintero T, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.1371/journal.pdig.0000514

51. Urbanek Z, Zielinski U, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.17219/acem/208596

52. Vasquez A, Alvez V, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.7759/cureus.104086

53. Wojcik H, Hendriksen W, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.1038/s41746-023-00852-5

54. Zielinski O, Ostrowski Z, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.1016/j.mayocpiqo.2022.09.004

55. Andric V, Vasquez A, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.1177/08404704241291226

Citation: Ben Kirsch-Wag, Stanislav Slavkovsky, Estibaliz Alcantud. "Radioligand Therapy Beyond Neuroendocrine Tumours: Dosimetry, Supply Chain and Access." Transl Med Ther J (2023):2; 010-018. DOI: 10.5281/zenodo.22649084